J Bone Miner Res 18:9–17PubMedCrossRef
34. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226PubMedCrossRef 35. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP (2008) Early responsiveness of women with osteoporosis to teriparatide Trichostatin A solubility dmso after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793PubMedCrossRef 36. Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24:1998–2006PubMedCrossRef 37. Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalska D, Pavo I (2010) Histomorphometric changes
by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int. doi:10.1007/s00198-009-1168-7 38. Lindsay R, Cosman F, Zhou H, Nieves JW, Bostrom M, Barbuto N, Dempster DW (2007) MAPK inhibitor Prior alendronate treatment does not inhibit the early stimulation of osteoblast activity in response to teriparatide. J Bone Miner Res 22(Suppl):S124, Abstract 39. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment
of patients with teriparatide. Curr Med Res Opin 22:61–66PubMedCrossRef 40. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529–535PubMedCrossRef”
“France, June 2010 Coordinators: C.L. Benhamou, C. Roux The publication of the proceedings of the 5th Bone Quality Seminar 2010 has been made possible through an educational grant from Servier Osteoporosis International”
“Introduction Osteoporosis in men is an increasing but under-appreciated clinical and public health problem with the lifetime risk of fracture selleck kinase inhibitor in men at age 50 years estimated at 21% . As in women, increasing age is one of the major determinants of osteoporosis and fracture risk in men. Most studies examining changes in bone health with age have focused on “areal” bone mineral density (g/cm2; BMDa)  as measured by dual-energy X-ray absorptiometry (DXA) [3–6]. There are limitations, however, in assessment of bone health using DXA. In particular, DXA tends to overestimate BMD in larger, and underestimate in smaller, bones.